Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > Drug GMP Report > Ask the Expert

Drug GMP Report

January 2012

Ask the Expert

Gordon Richman, vice president of Strategic Compliance Consulting, and general counsel of EduQuest, answered questions about how drugmakers should evaluate and respond to FDA Form 483s.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
RSS
Free Trial
Archives
Sample PDF

Related Articles

FDA Inspection Flap Prompts Alexion Risk Assessment Reform FDA Rejects Allergan’s Levadex Due to CMO Concerns Novartis 483 Highlights Rocky Remediation at Nebraska Plant Concerns with Contract Manufacturer Draw Complete Response for Allergan’s Levadex

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.